Literature DB >> 9224084

Ocular damage associated with proton pump inhibitors.

P S Schönhöfer1, B Werner, U Tröger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9224084      PMCID： PMC2126950          DOI： 10.1136/bmj.314.7097.1805

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.

Authors:  R M Martin; N R Dunn; S Freemantle; S Shakir
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 2.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

3.  Esomeprazole-induced rhabdomyolysis in a patient with heart failure.

Authors:  Uwe Tröger; Ines Reiche; Marilene S Jepsen; Christof Huth; Stefanie M Bode-Böger
Journal:  Intensive Care Med       Date:  2010-03-13       Impact factor: 17.440

4.  Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.

Authors:  Alice Capogrosso Sansone; Irma Convertino; Maria Teresa Galiulo; Stefano Salvadori; Stefania Pieroni; Tamara Knezevic; Stefania Mantarro; Alessandra Marino; Manfred Hauben; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

Review 5.  Proton Pump Inhibitors and Risk of Rhabdomyolysis.

Authors:  Scott J Duncan; Colin W Howden
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

6.  Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.

Authors:  Miranda Davies; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Do proton pump inhibitors protect against cancer progression in GERD?

Authors:  Tomoharu Miyashita; Furhawn A Shah; John W Harmon; Guy P Marti; Daisuke Matsui; Koichi Okamoto; Isamu Makino; Hironori Hayashi; Katsunobu Oyama; Hisatoshi Nakagawara; Hidehiro Tajima; Hideto Fujita; Hiroyuki Takamura; Manabu Murakami; Itasu Ninomiya; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Tetsuo Ohta
Journal:  Surg Today       Date:  2012-10-31       Impact factor: 2.549

8.  Omeprazole-associated rhabdomyolysis.

Authors:  Kumiko Tanaka; Taka-Aki Nakada; Ryuzo Abe; Sakae Itoga; Fumio Nomura; Shigeto Oda
Journal:  Crit Care       Date:  2014-07-24       Impact factor: 9.097

9.  Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  E A Lew; J R Pisegna; J A Starr; E F Soffer; C Forsmark; I M Modlin; J H Walsh; M Beg; W Bochenek; D C Metz
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

10.  Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory.

Authors:  Tigran Makunts; Sama Alpatty; Kelly C Lee; Rabia S Atayee; Ruben Abagyan
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.